Oncology (all articles)
Investigation: FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway.
2 Aug, 2021 | 00:09h | UTCNews release: Investigation finds nearly half of drugs granted FDA ‘fast track’ approval lack proven clinical benefit – The BMJ
Commentary: Over 100 Drugs Given Speedy Approvals Still Lack Proof of Clinical Efficacy – MedPage Today (free registration required)
European PanCare Follow Up Recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer.
1 Aug, 2021 | 23:59h | UTC
Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975-2016.
1 Aug, 2021 | 23:58h | UTCCommentary: Survival Trends for Adolescents and Young Adults With Cancer: 40-Year Analysis – The ASCO Post
Telehealth in Oncology: ASCO Standards and Practice Recommendations.
30 Jul, 2021 | 11:52h | UTCTelehealth in Oncology: ASCO Standards and Practice Recommendations – JCO Oncology Practice
ASCO Guideline Update: Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer.
30 Jul, 2021 | 11:51h | UTC
RCT: Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer.
30 Jul, 2021 | 11:43h | UTC
Commentary on Twitter
In postmenopausal women with hormone-receptor-positive breast cancer who had 5 yrs of AI, extending adjuvant endocrine therapy by 5 years provides no benefit over a 2-year extension but is associated with a greater risk of bone fracturehttps://t.co/YDxeQVu8B9
— K Pavithran (@drkpavithran) July 29, 2021
Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline.
30 Jul, 2021 | 11:49h | UTC
Cohort study: Postdiagnosis smoking cessation linked to reduced risk for lung cancer progression and mortality.
29 Jul, 2021 | 11:12h | UTCPostdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality: A Prospective Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentary: Never too late: Cancer centers push patients to quit smoking – STAT
Summary for Patients: Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Death
Commentary on Twitter
Research led by Paul Brennan, PhD, @mahdi_iarc, et al. of @IARCWHO found that quitting smoking after a #lungcancer diagnosis may extend life without cancer recurrence https://t.co/b0YAqqt7FM. pic.twitter.com/Sjl3ipoXLQ
— Annals of Int Med (@AnnalsofIM) July 26, 2021
ASTRO Guideline: Radiation therapy for treatment of soft tissue sarcoma in adults.
29 Jul, 2021 | 10:54h | UTCNews release: Astro Issues Clinical Guideline on Radiation Therapy for Soft Tissue Sarcoma in Adults
ESMO Guidelines: Soft tissue and visceral sarcomas.
29 Jul, 2021 | 10:53h | UTC
RCT: Real time remote symptom monitoring during chemotherapy for cancer may reduce symptom burden and improve quality of life.
26 Jul, 2021 | 02:18h | UTCCommentaries:
Remote 24-hour monitoring shows sizable, positive effect on cancer patients – BMJ
Remote Monitoring System Reduces Chemotherapy Symptom Burden – HealthDay
eSMART trial adds support for remote symptom monitoring in people with cancer – medwire News
Related:
Study: Cancer patients benefit from using automated device to manage their symptoms
Study: Web-Based Symptom Monitoring Increases Overall Survival in Lung Cancer
Commentary on Twitter
👇🏼 Results from an RCT, conducted at multiple centres across Europe, showing the benefits of remote patient monitoring and highlighting the vital role it will play in services going forward – congratulations @roma_maguire @Lisa_McCann_ and colleagues https://t.co/8zWrykJEjS
— Katie McMillan (@KathrynMc91) July 22, 2021
RCT: Sintilimab plus a bevacizumab biosimilar versus sorafenib in unresectable hepatocellular carcinoma.
22 Jul, 2021 | 10:47h | UTCSintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In a phase III trial involving 571 pts with unresectable HCC, the anti-PD-1 mAb sintilimab + the bevacizumab biosimilar IBI305 improved PFS (median 4.6 vs 2.8 months with sorafenib; HR 0.56, P <0.0001) & OS (median NR vs 10.4 months; HR 0.57, P <0.0001), https://t.co/UF43FGdMMy
— NatureRevClinOncol (@NatRevClinOncol) June 22, 2021
Oncology Medical Home: ASCO and COA Standards – “The OMH model is a system of care delivery that features coordinated, efficient, accessible, and evidence-based care and includes a process for measurement of outcomes to facilitate continuous quality improvement”.
22 Jul, 2021 | 10:49h | UTCOncology Medical Home: ASCO and COA Standards – JCO Oncology Practice
Commentary: Oncology Organizations Release New Standards for Medical Home Care – Pharmacy Times
Systematic review: Breast Reconstruction After Mastectomy.
22 Jul, 2021 | 10:45h | UTCBreast Reconstruction After Mastectomy – Agency for Healthcare Research and Quality
RCT: Central venous access devices (Hickman catheters vs. PICCs vs. PORTs) for the delivery of systemic anticancer therapy – “PORTs are more effective and safer than both Hickman and PICCs”.
21 Jul, 2021 | 10:42h | UTCCentral venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial – The Lancet (link to abstract – $ for full-text)
News release: Study highlights more effective and safe way to deliver chemotherapy – University of Glasgow
AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia.
16 Jul, 2021 | 10:46h | UTC
Commentary on Twitter
Out now in @AGA_CGH: AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia. Had great time working on this with @AasmaShaukatMD & @seth_crockett. Hope it's a useful reference! @AmerGastroAssn
https://t.co/UB5hFMq6hc pic.twitter.com/KwHeKjU2dk— Peter Liang, MD MPH (@petersliang) February 19, 2021
Radiation therapy-associated toxicity: Etiology, management, and prevention.
15 Jul, 2021 | 09:13h | UTC
US Report: Death rates are declining for many common cancers, including lung cancer and melanoma.
15 Jul, 2021 | 09:11h | UTCCommentaries: Death rates are declining for many common cancers in the U.S., report finds – STAT AND Annual report to the nation: Rapid decrease in lung cancer and melanoma deaths – American Cancer Society
Global burden of cancer attributable to alcohol consumption – “Globally, an estimated 741.300, or 4·1% of all new cases of cancer in 2020 were attributable to alcohol consumption”.
14 Jul, 2021 | 11:07h | UTCNews release: Alcohol consumption linked to more than 740,000 new cancer cases in 2020 – The Lancet
Commentaries: Alcohol caused 740,000 cancer cases globally last year – study – The Guardian AND Expert reaction to study of alcohol and cancer – Science Media Centre
RCT: Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma.
13 Jul, 2021 | 09:20h | UTC
Commentary on Twitter
Long-term outcomes from the NEOCRTEC5010 demonstrated the survival benefit of neoadjuvant chemoradiotherapy followed by surgery compared with surgery alone for patients with locally advanced esophageal squamous cell carcinoma https://t.co/UBBEEAynsy
— JAMA Surgery (@JAMASurgery) June 29, 2021
RCT: MRI can cut overdiagnoses in prostate-cancer screening by half.
9 Jul, 2021 | 10:03h | UTCMRI-Targeted or Standard Biopsy in Prostate Cancer Screening – New England Journal of Medicine (link to abstract – $ for full-text)
News release: MRI can cut overdiagnoses in prostate-cancer screening by half – Karolinska Institutet
Related articles: RCT: MRI-targeted biopsy safely reduces the need for biopsy in more than one-third of men at risk for prostate cancer AND Meta-Analysis: Negative Predictive Value of MRI in the Detection of Clinically Significant Prostate Cancer AND Study: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis AND Review: The Use of MRI and PET Imaging Studies for Prostate Cancer Management AND Meta-Analysis: MRI plus Targeted Biopsy vs. Systematic Biopsy Alone for the Diagnosis of Prostate Cancer AND Cochrane Review: MRI Pathway vs. Systematic Biopsy for Detecting Prostate Cancer AND Meta-analysis: Clinical Utility of MRI in the Decision-making Process Before Radical Prostatectomy AND Research: Biparametric MRI (simpler, faster) May Be Used to Exclude Aggressive Disease and Avoid Unnecessary Biopsies in Men with Clinical Suspicion of Prostate Cancer AND Research: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis AND Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer
Perspective | Should People With Immune Problems Get Third Vaccine Doses?
8 Jul, 2021 | 09:07h | UTCShould People With Immune Problems Get Third Vaccine Doses? – The New York Times (a few articles per month are free)
Related: [Preprint] 3rd AstraZeneca shot gives strong immunity. AND Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.
Study Commentary: Febrile Neutropenia – Procalcitonin vs. MASCC Score.
8 Jul, 2021 | 08:57h | UTCFebrile Neutropenia – Procalcitonin vs MASCC Score – Journal Feed
M-A: Pregnancy After Breast Cancer – “These results provide reassuring evidence on the safety of conceiving in BC survivors”.
6 Jul, 2021 | 09:55h | UTCPregnancy After Breast Cancer: A Systematic Review and Meta-Analysis – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Honored and excited to share our large #metanalysis presented at #SABCS20 now published in @ASCO_pubs #JCO providing solid and reassuring evidence on fetal and maternal safety of #pregnancy after prior #BreastCancer history@OncoAlert #SurvOnc #bcsm
Link: https://t.co/lgKQDeB2VS pic.twitter.com/rTpFKsrpMc— Matteo Lambertini, MD PhD (@matteolambe) July 1, 2021
Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers.
5 Jul, 2021 | 01:42h | UTCCommentaries: Expert reaction to review and analysis of observational studies on aspirin and cancer survival – Science Media Centre AND Major review of studies: Aspirin could cut risk of death in cancer patients by 20% – Cardiff University
“It is randomized trials that provide definitive evidence to consider changes to clinical practice. The results of this review provide impetus for cancer patients to consider participation in these trials” (from Science Media Centre)